PHARMACIE CTRE MEDICAL BOISRIPEAUX : revenue, balance sheet and financial ratios

PHARMACIE CTRE MEDICAL BOISRIPEAUX is a French company founded 35 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in LES ABYMES (97139), this company of category PME shows in 2020 a revenue of 6.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE CTRE MEDICAL BOISRIPEAUX (SIREN 379806599)
Indicator 2020 2019 2017 2016
Revenue 6 162 219 € 5 603 403 € 5 763 781 € 5 533 135 €
Net income 56 368 € -8 364 € -119 865 € 30 168 €
EBITDA 173 768 € -10 593 € 35 798 € 58 157 €
Net margin 0.9% -0.1% -2.1% 0.5%

Revenue and income statement

In 2020, PHARMACIE CTRE MEDICAL BOISRIPEAUX achieves revenue of 6.2 M€. Revenue is growing positively over 4 years (CAGR: +2.7%). Vs 2019: +10%. After deducting consumption (4.3 M€), gross margin stands at 1.9 M€, i.e. a rate of 30%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 174 k€, representing 2.8% of revenue. Positive scissor effect: EBITDA margin improves by +3.0 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 56 k€, i.e. 0.9% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2020) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

6 162 219 €

Gross margin (2020) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

1 867 578 €

EBITDA (2020) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

173 768 €

EBIT (2020) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

97 424 €

Net income (2020) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

56 368 €

EBITDA margin (2020) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

2.8%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 462%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 6%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.6 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 1.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2020) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

461.658%

Financial autonomy (2020) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

6.42%

Cash flow / Revenue (2020) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

1.938%

Repayment capacity (2020) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

5.589

Asset age ratio (2020) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

36.0%

Solvency indicators evolution
PHARMACIE CTRE MEDICAL BOISRIPEAUX

Sector positioning

Debt ratio
461.66 2020
2017
2019
2020
Q1: 33.22
Med: 96.81
Q3: 238.41
Average +50 pts over 3 years

In 2020, the debt ratio of PHARMACIE CTRE MEDICAL BO... (461.66) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
6.42% 2020
2017
2019
2020
Q1: 23.59%
Med: 41.65%
Q3: 61.93%
Watch

In 2020, the financial autonomy of PHARMACIE CTRE MEDICAL BO... (6.4%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Repayment capacity
5.59 years 2020
2017
2019
2020
Q1: 1.45 years
Med: 4.71 years
Q3: 9.29 years
Average +30 pts over 3 years

In 2020, the repayment capacity of PHARMACIE CTRE MEDICAL BO... (5.59) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 105.00. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 12.2x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2020) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

105.004

Interest coverage (2020) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

12.201

Liquidity indicators evolution
PHARMACIE CTRE MEDICAL BOISRIPEAUX

Sector positioning

Liquidity ratio
105.0 2020
2017
2019
2020
Q1: 133.13
Med: 181.9
Q3: 251.9
Watch +6 pts over 3 years

In 2020, the liquidity ratio of PHARMACIE CTRE MEDICAL BO... (105.00) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
12.2x 2020
2017
2019
2020
Q1: 0.68x
Med: 3.88x
Q3: 8.36x
Excellent

In 2020, the interest coverage of PHARMACIE CTRE MEDICAL BO... (12.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 11 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 77 days. Excellent situation: suppliers finance 66 days of the operating cycle (retail model). Inventory turnover is 50 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 71 days of revenue, i.e. 1.2 M€ to permanently finance.

Operating WCR (2020) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

1 213 711 €

Customer credit (2020) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

11 j

Supplier credit (2020) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

77 j

Inventory turnover (2020) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

50 j

WCR in days of revenue (2020) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

71 j

WCR and payment terms evolution
PHARMACIE CTRE MEDICAL BOISRIPEAUX

Positioning of PHARMACIE CTRE MEDICAL BOISRIPEAUX in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 180 transactions of similar company sales in 2020, the value of PHARMACIE CTRE MEDICAL BOISRIPEAUX is estimated at 2 498 736 € (range 2 016 880€ - 2 988 166€). With an EBITDA of 173 768€, the sector multiple of 9.7x is applied. The price/revenue ratio is 0.81x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2020
180 transactions
2016k€ 2498k€ 2988k€
2 498 736 € Range: 2 016 880€ - 2 988 166€
NAF 5 année 2020

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
173 768 € × 9.7x
Estimation 1 689 606 €
1 366 109€ - 2 265 852€
Revenue Multiple 30%
6 162 219 € × 0.81x
Estimation 4 982 025 €
4 091 965€ - 5 467 555€
Net Income Multiple 20%
56 368 € × 14.1x
Estimation 796 630 €
531 181€ - 1 074 868€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 180 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE CTRE MEDICAL BOISRIPEAUX with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE CTRE MEDICAL BOISRIPEAUX

What is the revenue of PHARMACIE CTRE MEDICAL BOISRIPEAUX ?

The revenue of PHARMACIE CTRE MEDICAL BOISRIPEAUX in 2020 is 6.2 M€.

Is PHARMACIE CTRE MEDICAL BOISRIPEAUX profitable?

Yes, PHARMACIE CTRE MEDICAL BOISRIPEAUX generated a net profit of 56 k€ in 2020.

Where is the headquarters of PHARMACIE CTRE MEDICAL BOISRIPEAUX ?

The headquarters of PHARMACIE CTRE MEDICAL BOISRIPEAUX is located in LES ABYMES (97139), in the department Guadeloupe.

Where to find the tax return of PHARMACIE CTRE MEDICAL BOISRIPEAUX ?

The tax return of PHARMACIE CTRE MEDICAL BOISRIPEAUX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE CTRE MEDICAL BOISRIPEAUX operate?

PHARMACIE CTRE MEDICAL BOISRIPEAUX operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.